New study reveals how blood cancer cells escape the immune system's natural killer cells

byUniversity of HelsinkiGraphical abstract. Credit:Immunity(2023). DOI: 10.1016/j.immuni.2023.11.008The advent of T-cell therapies, where cells of the immune system are directed towa

Updated on: January 26,2024

New study reveals how blood cancer cells escape the immune system's natural killer cells

byUniversity of HelsinkiGraphical abstract. Credit:Immunity(2023). DOI: 10.1016/j.immuni.2023.11.008The advent of T-cell therapies, where cells of the immune system are directed towa

Updated on:January 26,2024

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on: October 15,2023

PD-1/VEGFR-2 Inhibitor Combo Shows Durable Responses in Nasopharyngeal Carcinoma

February 10, 2023Ashling WahnerThe combination of camrelizumab and apatinib led to long-term antitumor activity with manageable toxicities in patients with recurrent or metastatic nasopharyngeal carci

Updated on:October 15,2023

Advanced imaging may help in clinical treatment of prostate cancer

byEuropean Association of UrologyCredit: Pixabay/CC0 Public DomainAn advanced imaging method is showing promise as a way to improve the diagnosis of prostate cancer by giving clinicians a cleare

Updated on: January 10,2024

Advanced imaging may help in clinical treatment of prostate cancer

byEuropean Association of UrologyCredit: Pixabay/CC0 Public DomainAn advanced imaging method is showing promise as a way to improve the diagnosis of prostate cancer by giving clinicians a cleare

Updated on:January 10,2024

Survivors of childhood cancers at risk for shortened life span

(HealthDay)—Survivors of childhood cancer remain at risk for shorter life spans, especially when they receive radiotherapy, according to a study published online Jan. 2 inJAMA Oncology.Jennifer

Updated on: December 20,2023

Survivors of childhood cancers at risk for shortened life span

(HealthDay)—Survivors of childhood cancer remain at risk for shorter life spans, especially when they receive radiotherapy, according to a study published online Jan. 2 inJAMA Oncology.Jennifer

Updated on:December 20,2023

Study uncovers the role of NETO2-mediated regulation in melanoma progression

by Frontiers JournalsCredit:Frontiers of Medicine(2023). DOI: 10.1007/s11684-022-0935-0Cong Peng and others at the Department of Dermatology, Xiangya Hospital, Central South University, Ch

Updated on: August 27,2024

Study uncovers the role of NETO2-mediated regulation in melanoma progression

by Frontiers JournalsCredit:Frontiers of Medicine(2023). DOI: 10.1007/s11684-022-0935-0Cong Peng and others at the Department of Dermatology, Xiangya Hospital, Central South University, Ch

Updated on:August 27,2024

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on: October 24,2023

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

August 29, 2017Jason HarrisPembrolizumab (Keytruda) induced an overall response rate of 25.9% and was well tolerated in patients with PD-L1–positive recurrent or metastatic nasopharyngeal carcinoma.Na

Updated on:October 24,2023

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20, 2022Megan HollaschAn analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.&

Updated on: October 17,2023

Multicenter Review Supports TKI Use in Patients With mRCC and Bone Metastases

September 20, 2022Megan HollaschAn analysis of patterns of care and outcomes for patients with metastatic renal cell carcinoma with bone metastases supported the role of TKIs as the standard of care.&

Updated on:October 17,2023

Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

byWolters Kluwer HealthCredit: Pixabay/CC0 Public DomainNipple-sparing mastectomy (NSM)—an increasingly popular option for women undergoing treatment for breast cancer—not only achieves good cos

Updated on: December 19,2023

Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

byWolters Kluwer HealthCredit: Pixabay/CC0 Public DomainNipple-sparing mastectomy (NSM)—an increasingly popular option for women undergoing treatment for breast cancer—not only achieves good cos

Updated on:December 19,2023

Study points to new possibilities for treating lung cancer patients

by Birgitte Svennevig,University of Southern DenmarkAn EMT-centric investigation of metabolic processes in a comprehensive lung cancer transcriptome profiles collection identified an inverse ass

Updated on: May 25,2024

Study points to new possibilities for treating lung cancer patients

by Birgitte Svennevig,University of Southern DenmarkAn EMT-centric investigation of metabolic processes in a comprehensive lung cancer transcriptome profiles collection identified an inverse ass

Updated on:May 25,2024

AI's Breakthroughs in Ovarian Cancer Diagnosis and Treatment

Updated on: June 12,2024

AI's Breakthroughs in Ovarian Cancer Diagnosis and Treatment

Updated on:June 12,2024

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances i

Updated on: November 21,2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances i

Updated on:November 21,2023

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on: December 22,2023

Addition of maintenance olaparib slows advanced ovarian cancer

(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovaria

Updated on:December 22,2023